Alpha-9 Theranostics Announces Oversubscribed $75 Million Series B Financing to Advance Portfolio of Radiopharmaceuticals for Cancer

Company is developing bespoke radiopharmaceuticals with capital efficient and rapid approach Proceeds to support progression of five candidates into the clinic, expansion of early-stage programs, accelerated growth of team, and completion of purpose-built research facilities BOSTON, Mass. and VANCOUVER, British Columbia, December 14, 2022 – Alpha-9 Theranostics Inc., a clinical stage company developing differentiated and […] The post Alpha-9 Theranostics Announces Oversubscribed $75 Million Series B Financing to Advance Portfolio of Radiopharmaceuticals for Cancer appeared first on Alpha-9 Onc